GlassScriptPhysician profile
Ashley Dilorenzo
NPI 1316300957
$9,324.61
in general payments reported to CMS, 2019-2025
22 companies · $3,028 in 2025
The $3,028 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2022: $407 · 2023: $1,859 · 2024: $3,793 · 2025: $3,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,471 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,471.05 |
| Education | $208.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.63 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $1,121.57 | 2023-2025 | Zoryve |
| Genzyme Corporation | $1,117.20 | 2023-2025 | |
| Incyte Corporation | $703.12 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $679.90 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $657.77 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $492.93 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $469.18 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $396.93 | 2019-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.29 | 2023-2025 | Spevigo |
| Pfizer INC. | $387.45 | 2024-2025 | |
| Galderma Laboratories, L.P. | $334.22 | 2022-2025 | Aklief, Epsolay, Oracea |
| Lilly USA, LLC | $314.87 | 2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $221.95 | 2024-2025 | Adbry, Anzupgo |
| Almirall LLC | $180.44 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $156.82 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $152.47 | 2024-2025 | Bimzelx |
| Organon LLC | $142.59 | 2023-2025 | Vtama, Hadlima |
| Botanix Sb INC | $120.65 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $39.83 | 2023-2024 | Poteligeo |
| Convatec INC. | $27.90 | 2024 | |
| Strata Skin Sciences, INC. | $19.90 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Dilorenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.